Genetic Immunity, InPlay: Company To Present At Phacilitate's 8th Annual European Vaccine Forum

Main Category: Genetics
Also Included In: Immune System / Vaccines
Article Date: 21 Jun 2009 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on an ongoing basis.

Genetic Immunity is pleased to announce that Dr. Julianna Lisziewicz, Chief Executive Officer of the Company, will be presenting "DermaVir Nanomedicine: The Next Generation DNA Vaccine" at Phacilitate's 8th annual European Vaccine Forum, to be held from June 22-24, 2009 Barcelona, Spain.

"I look forward to discussing the latest developments on our nanomedicine and dendritic cell targeting delivery system with conference attendees and to learn more about the progress of other companies active in the fields of immune therapy and vaccines. This event, just like the Bio International Convention in Atlanta, will give us many opportunities to look for partnerships and, or to reach for greater exposure of our immunotherapeutics technology," commented Julianna Lisziewicz, CEO of the Company.

Phacilitate is a specialist in the organization of exclusive events for leaders from the life sciences community. Their philosophy is simple -- to deliver the ultimate in strategic knowledge exchange and networking through flawless, personalized service. Phacilitate's 8th annual European Vaccine Forum will run in parallel this year to a new conference -- the Active Immunotherapeutics Forum. Dr. Lisziewicz will be attending both conferences.

About Genetic Immunity

Genetic Immunity is a US/Hungarian biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the Company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. http://www.geneticimmunity.com

Source
Power of the Dream Ventures